Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Brilinta (ticagrelor)
- daclatasvir
Interactions between your drugs
ticagrelor daclatasvir
Applies to: Brilinta (ticagrelor), daclatasvir
MONITOR: Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir. When 0.125 mg once daily of digoxin, a P-gp probe substrate, was administered with 60 mg once daily daclatasvir, digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 65% and 27%, respectively.
MANAGEMENT: Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2015) "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Norvasc
Norvasc (amlodipine) is a calcium channel blocker used to treat high blood pressure and angina ...
Caduet
Caduet (amlodipine and atorvastatin) is used to treat high blood pressure or angina in patients ...
Aceon
Aceon (perindopril) is an ACE inhibitor used to treat hypertension (high blood pressure). Includes ...
Katerzia
Katerzia is used for angina, coronary artery disease, high blood pressure
Norliqva
Norliqva is used for angina, coronary artery disease, high blood pressure
Isoxsuprine
Isoxsuprine is used for cerebrovascular insufficiency, coronary artery disease, raynaud's syndrome
Amlodipine/atorvastatin
Amlodipine/atorvastatin is used for angina, coronary artery disease, high blood pressure, high ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.